SEOUL (Reuters) -South Korean pharmaceutical company Celltrion said on Wednesday that it plans to invest up to 700 billion Korean won ($478.17 million) to expand capacity at its U.S. factory in response to U.S. tariffs and rising demand. ($1 = 1,463.9000 won) (Reporting by Hyunjoo JinEditing by Ed Davies) (The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
